JP2019515646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515646A5 JP2019515646A5 JP2018544554A JP2018544554A JP2019515646A5 JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5 JP 2018544554 A JP2018544554 A JP 2018544554A JP 2018544554 A JP2018544554 A JP 2018544554A JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5
- Authority
- JP
- Japan
- Prior art keywords
- binding member
- seq
- member according
- sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/EP2017/054367 WO2017144681A1 (en) | 2016-02-25 | 2017-02-24 | Binding members to pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515646A JP2019515646A (ja) | 2019-06-13 |
| JP2019515646A5 true JP2019515646A5 (enExample) | 2020-04-09 |
| JP7080819B2 JP7080819B2 (ja) | 2022-06-06 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20190048085A1 (enExample) |
| EP (3) | EP4086285A1 (enExample) |
| JP (3) | JP7080819B2 (enExample) |
| KR (2) | KR20180111870A (enExample) |
| CN (3) | CN108699153B (enExample) |
| AU (2) | AU2017224843A1 (enExample) |
| BR (2) | BR112018067698A2 (enExample) |
| CA (2) | CA3014001A1 (enExample) |
| ES (1) | ES2903408T3 (enExample) |
| RU (2) | RU2018128462A (enExample) |
| SG (2) | SG11201807188VA (enExample) |
| WO (2) | WO2017147383A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| KR20180111870A (ko) * | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| PT3551221T (pt) | 2016-12-08 | 2022-01-18 | Immatics Biotechnologies Gmbh | Novos recetores de células t e imunoterapia empregando os mesmos |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| IL321717A (en) | 2017-02-21 | 2025-08-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| CA3059634A1 (en) | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CA3057866A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| CN112218885B (zh) | 2017-12-20 | 2024-06-18 | 波赛达治疗公司 | Vcar组合物和使用方法 |
| KR102795692B1 (ko) | 2018-01-19 | 2025-04-16 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 키메라 항원 수용체를 발현하는 조절 t 세포 |
| EP3759146A1 (en) | 2018-03-02 | 2021-01-06 | CDR-Life AG | Trispecific antigen binding proteins |
| AU2019241345A1 (en) * | 2018-03-29 | 2020-10-15 | Adagene Inc. | Anti-PD-L1 antibodies and use thereof |
| CA3102744A1 (en) * | 2018-06-04 | 2019-12-12 | Diatheva S.R.L. | Anti-cd99 diabody or igg antibody and uses thereof |
| CN112543808A (zh) | 2018-06-21 | 2021-03-23 | 比莫根生物科技公司 | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 |
| EP3816187A4 (en) * | 2018-06-29 | 2022-08-03 | Y-Biologics Inc. | ANTIBODIES SPECIFIC TO BINDING TO LAG-3 AND USE THEREOF |
| AU2019301070B2 (en) | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| AU2019354395A1 (en) * | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| JP2022512766A (ja) * | 2018-10-17 | 2022-02-07 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| JP7571021B2 (ja) * | 2018-12-06 | 2024-10-22 | グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド | 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| CN113710689B (zh) * | 2019-01-28 | 2025-05-06 | 修普霍斯生物科学有限公司 | 选择性地将附着的异源分子递送至car细胞上的非天然nkg2d受体的修饰的非天然nkg2d配体 |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CN113710688A (zh) * | 2019-03-26 | 2021-11-26 | 加利福尼亚大学董事会 | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN118344479A (zh) * | 2019-06-12 | 2024-07-16 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| US20220331457A1 (en) * | 2019-07-02 | 2022-10-20 | Telix International Pty Ltd | Antibodies against caix with reduced affinity for the neonatal fc receptor |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| IL292462A (en) * | 2019-11-04 | 2022-06-01 | Inovio Pharmaceuticals Inc | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| WO2021113307A2 (en) * | 2019-12-02 | 2021-06-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| EP4123021A4 (en) * | 2020-03-23 | 2024-05-15 | Curigin Co.,Ltd. | STRUCTURE OF AN ONCOLYTIC VIRUS WITH BISPECIFIC NUCLEIC ACID MOLECULE |
| CN115667292A (zh) * | 2020-04-06 | 2023-01-31 | 朗格生物技术公共公益股份有限公司 | 模块化合成受体和使用方法 |
| IL298279A (en) * | 2020-04-17 | 2023-01-01 | Council Queensland Inst Medical Res | Immune cells with enhanced function |
| KR20230038139A (ko) * | 2020-05-14 | 2023-03-17 | 버투오소 빈코, 인크. | 인간화 cd38 및 icam1 항체 및 이의 용도 |
| EP4164696A1 (en) * | 2020-06-11 | 2023-04-19 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| WO2021262499A1 (en) * | 2020-06-25 | 2021-12-30 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| IL299764A (en) | 2020-07-10 | 2023-03-01 | Precigen Inc | Fusion constructs and methods for using them |
| JP2023548586A (ja) * | 2020-11-04 | 2023-11-17 | センティ バイオサイエンシズ インコーポレイテッド | タンパク質ペイロード放出 |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| JP2023551482A (ja) * | 2020-11-30 | 2023-12-08 | フレッド ハッチンソン キャンサー センター | Ｐｄ－ｌ１結合ペプチド及びペプチド複合体及びそれらの使用方法 |
| WO2022219155A1 (en) * | 2021-04-15 | 2022-10-20 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| CN118019842A (zh) * | 2021-07-01 | 2024-05-10 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| US20250179196A1 (en) * | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| WO2023019240A2 (en) | 2021-08-13 | 2023-02-16 | Inovio Pharmaceuticals Inc. | Combination therapy to treat brain cancer |
| CN118176017A (zh) * | 2021-10-26 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| JP2025504557A (ja) * | 2022-01-28 | 2025-02-12 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ナチュラルキラーｔ細胞及びそれを使用する方法 |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| EP2332989B1 (en) | 2002-05-22 | 2015-04-01 | ESBATech, an Alcon Biomedical Research Unit LLC | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| DK2158315T3 (en) | 2007-06-25 | 2016-06-06 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies and modified antibodies with improved functional properties |
| US9556265B2 (en) | 2008-06-25 | 2017-01-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| CN104004094B (zh) | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| ES2716298T3 (es) | 2011-09-16 | 2019-06-11 | Baylor College Medicine | El microentorno tumoral como diana mediante el uso de células NKT manipuladas |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CN104736168B (zh) * | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
| EP3467124A1 (en) * | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| EP2961831B1 (en) * | 2013-02-26 | 2020-06-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| CN107106665A (zh) * | 2014-06-06 | 2017-08-29 | 纪念斯隆-凯特琳癌症中心 | 靶向间皮素的嵌合抗原受体及其用途 |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| EP3699188A1 (en) | 2014-09-04 | 2020-08-26 | Cellectis | 5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| ES2844700T3 (es) | 2014-09-26 | 2021-07-22 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
| CN107002043A (zh) | 2014-10-31 | 2017-08-01 | 贝勒医学院 | 靶向肿瘤而非t细胞的存活素特异性t细胞受体 |
| IL320860A (en) | 2014-12-19 | 2025-07-01 | Dana Farber Cancer Inst Inc | Chimeric antigen receptors and methods of using them |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
-
2017
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja not_active Expired - Fee Related
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja not_active Expired - Fee Related
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515646A5 (enExample) | ||
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2022122927A (ja) | Ｃｄ３結合抗体 | |
| JP2011509245A5 (enExample) | ||
| JP2018183173A5 (enExample) | ||
| JP2017522892A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2019513009A5 (enExample) | ||
| JP2010500876A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2018537421A (ja) | Ｇｉｔｒアゴニスト | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| JP2017519501A5 (enExample) | ||
| JP2017518040A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| JP2010509931A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| NZ598670A (en) | Antibodies against glucagon receptor and their use | |
| JP2024001073A5 (enExample) |